🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

In this month’s blog, Gissoo DeCotiis, Global Head of Advocacy & Strategic Relations, shares how advocacy groups are meeting the needs of the diverse #BreastCancer community: bit.ly/3CvCYsW @SHAREing Tigerlily Foundation Susan G. Komen Sharsheret Living Beyond Breast Cancer

Need tips for managing your work life and cancer diagnosis? Join us at @CancerandCareers virtual West Coast Conference on Work & Cancer cancerandcareers.org/en/westcoast #CACWestCoast

Sharsheret goes to the The White House! Sharsheret's CEO Elana Silber meets with leaders in the cancer community to launch Cancer Moonshot's National Roundtables on Breast and Cervical Cancer. Follow along as we share snippets from this groundbreaking day.

In honor of #BreastCancerAwarenessMonth Sharsheret’s CEO Elana Silber joined First Lady Melania Trump for the launch of a series of roundtables with American Cancer Society. Sharsheret is doing such important work to support Jewish women living with breast and ovarian cancer.

This #BreastCancerAwarenessMonth, we’re honored to support the work of our grantee, Sharsheret, one of the nation’s leading Jewish cancer organizations.

Genetic results impact your treatment plan. Learn how Marissa's positive BRCA1 test impacted her breast cancer diagnosis. Watch Marissa's story: youtube.com/watch?v=5-m_Xp… The @sharsheretofficial BRCA Hereditary Cancer video series is made possible w/ support from AstraZeneca.

Click to watch as women w/ advanced cancer share inspirational stories, memories, feelings & advice ow.ly/EQ9G50LuL7t. This video series is part of the Living Legacies project made possible w/ generous support from Gilead Sciences & in partnership with Memories Live.

Sharsheret's Young Professionals Circle Casino Night is back on 12/17 🃏 🎲 Join us for a fun and meaningful evening of casino games, raffle prizes, food and drinks. Hurry! Prices go up on December 1st. 🎰 Register here: link.sharsheret.org/YPCasino

Congrats to our partner Pfizer Inc.: the U.S. FDA expanded the indication for IBRANCE® (palbociclib) to include its use in combination with an AI as initial endocrine-based therapy for the treatment of HR+/HER2- mBC, regardless of menopausal status.

Congrats to Sharsheret's partner, GE HealthCare: the NCCN Guidelines now recommend F-18 fluoroestradiol (Cerianna) for ER+ positive mBC systemic staging workup. Read more: ow.ly/U3sE50OI2jf #Sharsheret #GEHealthCare #NCCN #F18fluoroestradiol #Cerianna

News from Sharsheret's partner AstraZeneca: Capivasertib in combination with FASLODEX® (fulvestrant) granted Priority Review in the US for patients with advanced HR-positive breast cancer. ow.ly/2A7Y50OPETe

Our partner @SeagenGlobal announces: Seagen Phase 3 Trial of TUKYSA® (tucatinib) in Combination with Antibody-Drug Conjugate ado-trastuzumab emtansine Meets Primary Endpoint of Progression-Free Survival in Patients with Previously Treated HER2-Positive Metastatic Breast Cancer

The CDC’s Div of Cancer Prevention & Control launched the My Family Health Portrait: Cancer app, that helps individuals collect their family’s history of cancer & learn their risk for breast, ovarian & colorectal cancers. The app is available on Google Play & the App Store.

Sharsheret stands with Israel and prays for lasting peace.

Genetic testing affects your children. Learn how Kerith spoke to her children about her positive BRCA test. Watch Kerith’s story: youtube.com/watch?v=p-M3c4… AstraZenecaUS

Our partner, AstraZenecaUS announced that ENHERTU® (fam-trastuzumab deruxtecan-nxki) has been approved by the US FDA for the treatment of adult patients with unresectable or metastatic HER2-positive solid tumors who have received prior systemic treatment.

Congratulations to Sharsheret partner Daiichi Sankyo for FDA approval of datopotamab deruxtecan-dlnk for unresectable or metastatic, HR-positive, HER2-negative breast cancer.

#SharsheretPinkDay is only one week away! A community of thousands will join together to raise awareness about breast cancer and ovarian cancer, and help save lives through education. Sharsheret Pink Day is proudly sponsored in part by Merck.

Congrats to our partners Gilead Sciences and Merck on Trodelvy® Plus Keytruda® that Demonstrates a Statistically Significant and Clinically Meaningful Improvement in Progression Free Survival in Patients With Previously Untreated PD-L1 Metastatic TNBC gilead.inc/42KdhSV

Congratulations to Genentech on this report